Z-VDVAD-FMK

• UNSPSC Description:

  Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis[1][2][3].

• Target Antigen:

  Caspase

• Type:

  Peptides

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/z-vdvad-fmk.html

• Purity:

  98.0

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](C(C)C)C(N[C@@H](CC(OC)=O)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(CF)=O)CC(OC)=O)=O)=O)C(C)C)=O)=O)OCC1=CC=CC=C1

• Molecular Weight:

  695.73

• References & Citations:

  [1]S Gamen, et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000 Jul 10;258(1):223-35. |[2]Cédric Sapet, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006 Sep 15;108(6):1868-76. |[3]Simon W Rabkin, et al. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol. 2003 Dec 15;193(3):346-55.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  210344-92-6